📢 Reminder
Join us for a #dengue side event to explore:
🔬 Integrated surveillance and data-driven decision-making
💊 R&D for new diagnostics, vaccines, and treatments
🤝 Regional cooperation and equitable access to health technologies
Info & registration👉 community.pasteur-network.org/events/208484
What if we told you that the secret to developing a life-saving sleeping sickness pill was making it look... exactly like a plain white tablet? 💊🧐 Dr. Stephen Robinson of @dndi.org breaks down the fascinating science of turning complex molecules into affordable medicine https://bit.ly/4sIj8Uz
Thanks for sharing!
A new study in BMJ Public Health shows current models predicting outcomes from visceral leishmaniasis are outdated, at high risk of bias, & miss regions like South Asia. None predict relapse or PKDL, only death. The authors urge caution when using them. Read more: doi.org/10.1136/bmjph-2024-001196
As a trusted steward of our financial integrity, the Board Treasurer helps ensure that DNDi remains accountable, sustainable, and equipped to deliver on our mission.
📆 Deadline: 27 April
👉 Details & how to apply: dndi.org/news/2026/dn...
📣 Help us spread the word!
When Jaqueline was diagnosed with cutaneous #leishmaniasis at 10, she endured painful injections & walked 13k to receive treatment at the health unit.
We aim to develop an entirely new generation of all-oral medicines that make treatment easier for every patient.
youtube.com/shorts/g5c15...
MedChemica, Diamond, CMD & DNDi are partners in the ASAP consortium, an open-science project aimed at discovering & developing new medicines against viruses of pandemic potential, including coronaviruses & dengue virus.
More about ASAP: dndi.org/research-dev... (3/3)
‘Our partners @diamondlightsource.bsky.social & @cmd.ox.ac.uk are analyzing the molecular structures of around 10 new compounds most weeks. We still have a lot to do, but this is clearly the way to tackle dengue and deliver promising new drug candidates that we can advance to the clinic.' (2/3)
'Every two weeks we now generate more lead‑optimization structural data on #dengue than we did in the previous two decades combined. The pace of the ASAP open-source project is astounding,' said @griffen-ed.bsky.social, technical director @medchemica.com. (1/3)
How does acoziborole kill sleeping sickness parasites? A fascinating deep dive into the chemistry behind our new medicine, its molecular structure and its distinctive feature: a boron-based scaffold called benzoxaborole.
By @chemistryworld.com www.chemistryworld.com/news/boron-p...
🤔 Why are some medicines injectable, but others come as tablets? What are the challenges of manufacturing drugs for NTDs? Why is acoziborole white?
Dr Stephen Robinson, our Pharmaceutical Development Director, answers all these questions (& more) here👇
youtu.be/7KvGr_kux-E
Join us for a #dengue roundtable side event to explore:
🔬 Integrated surveillance and data-driven decision-making
💊 R&D for new diagnostics, vaccines, and treatments
🤝 Regional cooperation and equitable access to health technologies
Info & registration👉 community.pasteur-network.org/events/208484
For too long, pregnant & breastfeeding women have been left out of clinical studies. The @britpharmsoc.bsky.social calls to:
👉 Include them when appropriate
👉 Strengthen safety & effectiveness data
👉 Give women clear & accessible information
🔗 bit.ly/4bKA6tW
Our statement at the 6th meeting of the Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement⤵️ dndi.org/statements/2...
"[Acoziborole] can dramatically simplify patient care, improve access to treatment and accelerate progress toward the elimination of sleeping sickness. It is a transformative tool," says Dr Priotto, @who.int.
Read more about our new treatment in @npr.org: www.npr.org/2026/03/16/g...
One dose. No hospitalization. @tv5monde.bsky.social travelled to Kasai, DRC, to meet former patients & healthcare workers using acoziborole, our new treatment for sleeping sickness. Their reportage shows how it could transform care & help eliminate this disease.⤵️ www.youtube.com/watch?v=lz4R...
We are very appreciative of the funding that EDCTP and many other donors and in-kind partners provided in the development of this game-changing treatment for sleeping sickness. Such long-term support makes R&D innovation possible!
Great to see the progress made by @dndi.org against #Chagas disease! dndi.org/news/2026/20...
🐍 Snakebites affect 1.8-2.7 million people each year. The disease is deeply neglected and patients need better access to antivenoms.
A Global Snakebite Taskforce report urges on govs and funders to invest, including in R&D.
By SciDev.Net [in French]
www.scidev.net/afrique-sub-...
In 2014, I visited eastern DRC, where @msf.org teams were treating sleeping sickness - the only available treatment was a drug so toxic it killed 1 in 20 patients. In 2026 I'm so proud that, thanks to @dndi.org, patients can be cured with a single dose of a groundbreaking new oral drug, acoziborole.
@novo-nordisk.bsky.social has renewed its support to DNDi and India’s THSTI to advance the development of a novel broad‑spectrum antiviral candidate targeting influenza and other viruses of pandemic potential, and strengthen pre-clinical research capacity for #pandemic preparedness.
👉 bit.ly/3N6Eo6y
Dr Wilfried remembers treating sleeping sickness patients with the old medicine which was so toxic it killed 1 in 20 patients.
💊 Acoziborole is a revolution since those dark days: it cures the disease with one-day treatment course & is effective for both stages of the disease. #1Dose1Cure
Thank you @msf.org for your unwavering support reaching this historic milestone for sleeping sickness! 🧡
Thank you for sharing this great news for people affected by sleeping sickness! 🧡
🚀 Huge news for people living with #sleepingsickness!
Acoziborole, a one-day, single-dose oral treatment developed with Sanofi, has received a positive opinion from @ema.europa.eu for the treatment of the most common form of sleeping sickness.
👉 bit.ly/46ZFpEi
Neonatal sepsis remains a leading cause of morbidity & mortality worldwide. Clinical trials like NeoSep1 Part 2 are reclaiming the narrative for newborn survival in the Global South.
👏 Congratulations @gardp.bsky.social & partners for setting a new standard for neonatal healthcare. #AMR
Today marks the launch of the CEPI 3.0 Investment Case and Strategy.
CEPI 3.0 – our 2027-2031 strategy - is the next step in CEPI’s mission to transform the way the world tackles epidemic and pandemic threats.
Discover more in the press release ⬇️
A Phase I study in healthy African adults assessed oxfendazole, a promising option for filarial diseases such as onchocerciasis. The findings suggest that a five day course of 400 mg daily, or 50 mg twice daily, reaches target exposure with low safety concerns. @PLOSNTDs doi.org/10.1002/psp4...
The future of African public health must be collaborative, data-driven & above all, people-centred.
The recent partnership between @dndi.org & @aphrc.bsky.social will be a gamechanger in strengthening the health ecosystem at large. #HealthEquity
Read more🔗 bit.ly/4tynePW
We’re at the 16th KEMRI Annual Scientific & Health (KASH) Conference 2026! Visit the DNDi booth to meet our team and learn about our work delivering safe, effective, and affordable treatments for neglected diseases. #KASH2026
